【摘要】 三阴性乳腺癌（TNBC）作为最具侵袭性的乳腺癌亚型，具有复发率高、死亡率高、治疗方法少等特点。核糖核酸干扰（RNA interference,RNAi）疗法可高效地调控靶标基因及相关下游通路，与化疗药物等联合应用，能够显著改善TNBC治疗效果，对基因调控和疾病治疗有重要意义。然而，RNA作为药物易被核酸酶降解、易被免疫系统识别及难以进行跨膜运输，因此设计靶向药物递送系统是RNA药物开发的重要目标。通过对抗TNBC的RNA药物递送系统进行综述并对其未来发展方向进行展望，以期为RNA药物的研发提供参考，促进RNA药物临床转化。更多还原

【Abstract】 Triple negative breast cancer(TNBC) as the most aggressive subtype of breast cancer, is characterized by high recurrence rate,high mortality, and few treatment methods. RNA interference(RNAi) therapy can efficiently regulate target genes and related downstream pathways, and combined with chemotherapy drugs, improving therapy of TNBC, which is of great significance for gene regulation and disease treatment. However, RNA is easily degraded by nucleases, recognized by the immune system, and is difficult to transport across membranes. Therefore, designing precise targeting drug delivery systems is an important goal in the development of RNA drugs. The paper provides a comprehensive review of the anti-TNBC RNA drug delivery system and offers insights into its future development direction,aiming to serve as a valuable reference for RNA drug research and development, as well as to facilitate the clinical translation of RNA drugs.更多还原